Skip to main content
SpringerLink
Log in

The natural history of melanoma, including the pattern of metastatic spread and the biological basis for metastases — staging of melanoma

  • Chapter
Current Research and Clinical Management of Melanoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 65))

Abstract

Melanomas are complex and biologically heterogeneous tumors whose clinical behavior varies from indolent to extremely aggressive. As with any malignancy, it is important to be able to stage melanomas to allow the prediction of clinical behavior for prognosis, treatment determination, and analysis of end results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. McNeer G, Das Gupta T. 1964. Prognosis in malignant melanoma. Surgery 56:512–518.

    Google Scholar 

  2. Clark WH, Jr., From L, Bernardino EA, Mihn MC. 1969. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705–726.

    PubMed  Google Scholar 

  3. Breslow A. 1970. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902–908.

    Article  PubMed  CAS  Google Scholar 

  4. Wanebo HJ, Woodruff J, Fortner JG. 1975. Malignant melanoma of the extremities: A clinicopathologic study using levels of invasion (microstage). Cancer 35:666–676.

    Article  PubMed  CAS  Google Scholar 

  5. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. 1978. A multifactorial analysis of melanoma: Prognostic histopathologic features comparing Clark’s and Breslow’s staging methods. Ann Surg 188:732–742.

    Article  PubMed  CAS  Google Scholar 

  6. Fortner JG, Woodruff J, Schottenfeld D, Maclean B. 1977. Biostatistical basis of elective node dissection for malignant melanoma. Ann Surg 186:101–103.

    Article  PubMed  CAS  Google Scholar 

  7. Goldman LI. 1980. Decisions in the management of cutaneous malignant melanoma. Semin Oncol 7:370–375.

    PubMed  CAS  Google Scholar 

  8. Roses DF, Harris MN, Hidalgo D, Valensi QJ, Dubin N. 1982. Primary melanoma thickness correlated with regional lymph node metastases. Arch Surg 117:921–923.

    Article  PubMed  CAS  Google Scholar 

  9. Holmes EC, Moseley HS, Morton DL, Clark W, Robinson D, Urist MM. 1977. A rational approach to the surgical management of melanoma. Ann Surg 186:481–490.

    Article  PubMed  CAS  Google Scholar 

  10. Balch CM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA. 1979. Tumor thickness as a guide to surgical management of clinical Stage I melanoma patients. Cancer 43:883–888.

    Article  PubMed  CAS  Google Scholar 

  11. Berdeaux DH, Meyskens FL, Jr., Parks B, Tong T, Loescher L, Moon TE. 1989. Cutaneous malignant melanoma. Cancer 63:4130–1436.

    Article  Google Scholar 

  12. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Vascinelli N, Claudio F, Ikonopisov RL, Javorski W, Kulakowski A, Lacour J, Lejeune F, Mechl Z, Morabito A, Rode I, Sergeev S, van Slooten E, Szczygiel K, Trapeznikov NN, Wagner RI. 1982. Delayed regional lymph node dissection in Stage I melanoma of the skin of the lower extremities. Cancer 49:2420–2430.

    Article  PubMed  CAS  Google Scholar 

  13. McCarthy WH, Shaw HW, Thompson JF, Milton GW. 1988. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 166:497–502.

    PubMed  CAS  Google Scholar 

  14. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. 1983. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (Stage III). J Clin Oncol 1:126–134.

    PubMed  CAS  Google Scholar 

  15. Amer MH, Al-Sarraf M, Vaitkevicius VK. 1979. Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 149:687–692.

    PubMed  CAS  Google Scholar 

  16. Nambisan RN, Alexiou G, Reese PA, Karakousis CP. 1987. Early metastatic patterns and survival in malignant melanoma. J Surg Oncol 34:248–252.

    Article  PubMed  CAS  Google Scholar 

  17. Budman DR, Camacho E, Wittes RE. 1978. The current causes of death in patients with malignant melanoma. Eur J Cancer 14:327–330.

    Article  PubMed  CAS  Google Scholar 

  18. Lee YTN. 1980. Malignant melanoma: Pattern of metastasis. Cancer Ann 30:137–142.

    CAS  Google Scholar 

  19. De La Monte SM, Moore GW, Hurchins GM. 1983. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 43:3427–3433.

    PubMed  Google Scholar 

  20. Nicolson GL, Poste G. 1982. Tumor cell diversity and host responses in cancer metastases, part I. Properties of metastatic cells. Curr Prob Cancer 2:1–81.

    Article  Google Scholar 

  21. Fidler IJ, Nicolson GL. 1981. Immunobiology of experimental metastatic melanoma. In JJ Marcholonis, M Homer, IJ Fuller (eds), Cancer Biology Reviews, Vol 2. New York: Marcel Dekker, pp 171–234.

    Google Scholar 

  22. Nicolson GL. 1984. Cell surface molecules and tumor metastases. Cancer Res 150:3–22.

    CAS  Google Scholar 

  23. Belloni PN, Nicolson GL. 1985. Differential protein expression in organ derived endothelial microvessels and parenchyma. J Cell Biochem Suppl 9A, 147.

    Google Scholar 

  24. Nakajima M, Irimura T, Nicolson GL. 1987. Basement membrane degradative enzymes and tumor metastases. Cancer Bull 39:142–149.

    Google Scholar 

  25. Reading CL. 1984. Carbohydrate structure, biological recognition, and immunofunction. In RJ Ivatt (ed), The Biology of Glycoproteins. New York: Plenum Press, pp 235–321.

    Chapter  Google Scholar 

  26. Eudes SA. 1990. The role of oncogenes in metastasis. In D Carney, K Sikera (eds), Genes and Cancer. Chichester, England: John Wites & Sons, pp 85–96.

    Google Scholar 

  27. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C, Ferrone S. 1984. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 44:3930–3935.

    PubMed  CAS  Google Scholar 

  28. Holzmann B, Brocker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmuller G, Johnson JP. 1987. Tumor progression in human malignant melanoma: Five stages defined by their antigenic phenotypes. Int J Cancer 39:466–471.

    Article  PubMed  CAS  Google Scholar 

  29. van Vreeswijk HV, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. 1988. Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Derm 90:755–760.

    Article  PubMed  Google Scholar 

  30. Moretti S, Massobrio R, Brogelli L, Novelli M, Giannotti B, Bernengo MG. 1990. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Derm 95:320–324.

    Article  PubMed  CAS  Google Scholar 

  31. van Muijen GNP, Cornelissen I, Jansen C, Ruiter DJ. 1989. Progression markers in metastasizing human melanoma cells xenografted to nude mice (review). Anticancer Res 9:879–884.

    PubMed  Google Scholar 

  32. Maio M, Gulwani B, Langer JA, Kerbel RS, Duigou GJ, Fisher PB, Ferrone S. 1989. Modulation by interferons of HLA antigen, high-molecular-weight melanoma-associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. Cancer Res 49:2980–2987.

    PubMed  CAS  Google Scholar 

  33. Mortarini R, Belli F, Parmiani G, Anichini A. 1990. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3, and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rILI-ß, rTNF-α, rlFN-γ, rIL4, and their combinations. Int J Cancer 45:334–341.

    Article  PubMed  CAS  Google Scholar 

  34. Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R, Orfanos CE. 1990. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: Changes of proliferation, melanin synthesis, and immunophenotype. J Invest Derm 95:231S–237S.

    Article  PubMed  CAS  Google Scholar 

  35. Maio M, Gulwani B, Morgano A, Ferrone S. 1989. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int J Cancer 44:554–559.

    Article  PubMed  CAS  Google Scholar 

  36. Zouboulis CC, Schroder K, Garbe C, Krasagakis K, Kruger S, Orfanos CE. 1990. Cytostatic and cytotoxic effects of recombinant tumor necrosis factor-alpha on sensitive human melanoma cells in vitro may result in selection of cells with enhanced markers of malignancy. J Invest Derm 95:223S–230S.

    Article  PubMed  CAS  Google Scholar 

  37. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S. 1988. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019–1025.

    PubMed  Google Scholar 

  38. Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller G. 1989. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastatsis. Proc Natl Acad Sci USA 86:641–644.

    Article  PubMed  CAS  Google Scholar 

  39. Lehmann JM, Riethmuller G, Johnson JP. 1989. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86:9891–9895.

    Article  PubMed  CAS  Google Scholar 

  40. Johnson JP. 1991. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastas Rev 10:11–22.

    Article  CAS  Google Scholar 

  41. Natali P, Nicotra MR, Cavaliere R, Bigotti A, Romano G, Temponi M, Ferrone S. 1990. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 50:1271–1278.

    PubMed  CAS  Google Scholar 

  42. Harning R, Mainolfi E, Bystryn JC, Henn M, Merluzzi VJ, Rothlein R. 1991. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 51:5003–5005.

    PubMed  CAS  Google Scholar 

  43. Hansen NL, Ralfkiaer E, Hou-Jensen K, Thomsen K, Drzewiecki KT, Rothlein R, Vejlsgaard GL. 1991. Expression of intercellular adhesion molecule-1 (ICAM-1) in benign naevi and malignant melanomas. Acta Derm Venereol 71:48–51.

    PubMed  CAS  Google Scholar 

  44. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH, Gilmore LB, Seftor REB, Nakajima M, Hendrix MJC. 1991. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 47:227–237.

    Article  PubMed  CAS  Google Scholar 

  45. Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G, Johnson JP. 1987. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47:841–845.

    PubMed  CAS  Google Scholar 

  46. Linnemann D, Raz A, Bock E. 1989. Differential expression of cell adhesion molecules in variants of K1735 melanoma cells differing in metastatic capacity. Int J Cancer 43:709–712.

    Article  PubMed  CAS  Google Scholar 

  47. Rice GE, Bevilacqua MP. 1989. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 246:1303–1306.

    Article  PubMed  CAS  Google Scholar 

  48. Zhu D, Cheng C, Pauli BU. 1991. Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule. Proc Natl Acad Sci USA 88:9568–9572.

    Article  PubMed  CAS  Google Scholar 

  49. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. 1988. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 41:562–567.

    Article  PubMed  CAS  Google Scholar 

  50. Burrows FJ, Haskard DO, Hart IR, Marshall JF, Selkirk S, Poole S, Thorpe PE. 1991. Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. Cancer Res 51:4768–4775.

    PubMed  CAS  Google Scholar 

  51. Mortarini R, Anichini A, Parmiani G. 1991. Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins. Int J Cancer 47:551–559.

    Article  PubMed  CAS  Google Scholar 

  52. Anichini A, Mortarini R, Supino R, Parmiani G. 1990. Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile, and invasive ability. Int J Cancer 46:508–515.

    Article  PubMed  CAS  Google Scholar 

  53. Braakman E, Goedegebuure PS, Vreugdenhil RJ, Segal DM, Shaw S, Bolhuis RLH. 1990. ICAM-melanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int J Cancer 46:475–480.

    Article  PubMed  CAS  Google Scholar 

  54. Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB, Kurnick JT. 1992. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes. Cancer 69:1165–1173.

    Article  PubMed  CAS  Google Scholar 

  55. Topalian SL, Kasid A, Rosenburg SA. 1990. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. J Immunol 144:4487–4495.

    PubMed  CAS  Google Scholar 

  56. Liotta LA, Rao CN, Wewer UM. 1986. Biochemical interactions of tumor cells with the basement membrane. Ann Rev Biochem 55:1037–57.

    Article  PubMed  CAS  Google Scholar 

  57. Cheresh DA. 1991. Structure, function and biological properties of integrin αvβ3 on human melanoma cells. Cancer Metast Rev 10:3–10.

    Article  CAS  Google Scholar 

  58. Kramer RH, Vu M, Cheng YF, Ramos DM. 1991. Integrin expression in malignant melanoma. Cancer Metast Rev 10:49–59.

    Article  CAS  Google Scholar 

  59. Hart IR, Birch M, Marshall JF. 1991. Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metast Rev 10:115–128.

    Article  CAS  Google Scholar 

  60. Hemmler ME. 1990. VLA proteins in the integrin family structure, function, and their role on leukocytes. Annu Rev Immunol 8:365–400.

    Article  Google Scholar 

  61. Kramer RH, McDonald KA, Crowley E, Ramos DM, Damsky CH. 1989. Melanoma cell adhesion to basement membrane mediated by integrin-related complexes. Cancer Res 49:393–402.

    PubMed  CAS  Google Scholar 

  62. Ramos DM, Berston ED, Kramer RH. 1990. Analysis of integrin receptors for laminin and type IV collagen on metastatic B16 melanoma cells. Cancer Res 50:728–734.

    PubMed  CAS  Google Scholar 

  63. Oz OK, Campbell A, Tao T. 1989. Reduced cell adhesion to fibronectin and laminin is associated with altered glycosylation of β1 integrins in a weakly metastatic glycosylation mutant. Int J Cancer 44:343–347.

    Article  PubMed  CAS  Google Scholar 

  64. Kramer RH, Marks N. 1989. Identification of integrin collagen receptors on human melanoma cells. J Biol Chem 264:4684–4688.

    PubMed  CAS  Google Scholar 

  65. van Muijen GNP, Jansen KFJ, Cornelissen LMHA, Smeets DFCM, Beck JLM, Ruiter DJ. 1991. Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int J Cancer 48:85–91.

    Article  PubMed  Google Scholar 

  66. van Muijen GNP, Cornelissen LMHA, Jansen CFJ, Figdor CG, Johnson JP, Brocker EB, Ruiter DJ. 1991. Antigen expression of metastasizing and nonmetastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastas 9:259–272.

    Article  Google Scholar 

  67. Kramer RH, McDonald KA, Vu MP. 1989. Human melanoma cells express a novel integrin receptor for laminin. J Biol Chem 264:15642–15649.

    PubMed  CAS  Google Scholar 

  68. Albini A, Aukerman SL, Ogle RC, Noonan DM, Fridman R, Martin GR, Fidler IJ. 1989. The in vitro invasiveness and interactions with laminin of K-1735 melanoma cells. Evidence for different laminin-binding affinities in high and low metastatic variants. Clin Exp Metastasis 7:437–451.

    Article  PubMed  CAS  Google Scholar 

  69. Albeda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. 1990. Integrin distribution in malignant melanoma: Association of the β3 subunit with tumor progression. Cancer Res 50:6757–6764.

    Google Scholar 

  70. McGregor BC, McGregor JL, Weiss LM, Wood GS, Hu CH, Boukerche H, Warnke RA. 1989. Presence of cytoadhesins (IIb-IIIa-like glycoproteins) on human metastatic melanomas but not on benign melanocytes. Am J Clin Pathol 92:495–499.

    PubMed  CAS  Google Scholar 

  71. Boukerche H, Berthier-Vergnes O, Tabone E, Dore JF, Leung LK, McGregor JL. 1989. Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex. Blood 74:658–663.

    PubMed  CAS  Google Scholar 

  72. Tuszynski GP, Karczewski J, Smith L, Murphy A, Rothman VL, Knudsen KA. 1989. The GPIIb-IIIa-like complex may function as a human melanoma cell adhesion receptor for thrombospondin. Exp Cell Res 182:473–470.

    Article  PubMed  CAS  Google Scholar 

  73. Humphries MJ, Olden K, Yamada KM. 1986. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233:467–470.

    Article  PubMed  CAS  Google Scholar 

  74. Saiki I, Iida J, Murata J, Ogawa R, Nishi N, Sugimura K, Tokura S, Azuma I. 1989. Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules. Cancer Res 49:3815–3822.

    PubMed  CAS  Google Scholar 

  75. Kumagai H, Tajima M, Yeno Y, Giga-Hama Y, Ohba M. 1991. Effect of cyclic RGD peptide on cell adhesion and tumor metastasis. Biochem Biophys Res Commun 177:74–82.

    Article  PubMed  CAS  Google Scholar 

  76. Soszka T, Knudsen KA, Beviglia L, Rossi C, Poggi, Niewiarowski S. 1991. Inhibition of murine melanoma cell-matrix adhesion and experimental metastasis by albolabrin, and RGD-containing peptide isolated from the venom of Trimeresurus albolabris. Exp Cell Res 196:6–12.

    Article  PubMed  CAS  Google Scholar 

  77. Boukerche H, Berthier-Vergnes O, Bailly M, Dore JF, Leung LK, McGregor JL. 1989. A monoclonal antibody (LYP18) directed against the blood platelet glycoprotein Ilb/IIIa complex inhibits human melanoma cell growth in vivo. Blood 74:909–912.

    PubMed  CAS  Google Scholar 

  78. Giavazzi R, Garofalo A, Bani MR, Abbate M, Ghezzi P, Boraschi D, Mantovani A, Dejana E. 1990. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res 50:4771–4775.

    PubMed  CAS  Google Scholar 

  79. Lauri D, Bertomeu MC, Orr FW, Bastida E, Suader D, Buchanan MR. 1990. Interleukin-1 increases tumor cell adhesion to endothelial cell through an RGD dependent mechanism: In vitro and in vivo studies. Clin Exp Metastasis 8:27–32.

    Article  PubMed  CAS  Google Scholar 

  80. Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, Hendrix MJC. 1992. Role of the αvβ3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 89:1557–1561.

    Article  PubMed  CAS  Google Scholar 

  81. McCarthy JB, Hagen ST, Furcht LT. 1986. Human fibronectin contains distinct adhesion-and motility-promoting domains for metastatic melanoma cells. J Cell Biol 102:179–188.

    Article  PubMed  CAS  Google Scholar 

  82. Asch AS, Tepler J, Silbiger S, Nachman RL. 1991. Cellular attachment to thrombospondin. J Biol Chem 266:1740–1745.

    PubMed  CAS  Google Scholar 

  83. Cheresh DA, Pytela R, Pierschbacher MD, Klier FG, Ruoslahti E, Reisfeld RA. 1987. An arg-gly-asp-directed receptor on the surface of human melanoma cells exists in a divalent cation-dependent functional complex with the disialoganglioside GD2. J Cell Biol 105:1163–1173.

    Article  PubMed  CAS  Google Scholar 

  84. Burns GF, Lucas CM, Krissansen GW, Werkmeister JA, Scanion DB, Simpson RJ, Vadas MA. 1988. Synergisms between membrane gangliosides and arg-gly-asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cells. J Cell Biol 107:1225–1230.

    Article  PubMed  CAS  Google Scholar 

  85. Reisfeld RA, Cheresh DA. 1987. Human tumor antigens. Adv Immunol 40:323–377.

    Article  PubMed  CAS  Google Scholar 

  86. Carubia JM, Yu RK, Macala LJ, Kirkwood JM, Varga JM. 1984. Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 120:500–504.

    Article  PubMed  CAS  Google Scholar 

  87. Hersey P, Jamal O, Henderson C, Zarwadi I, D’Alessandro G. 1988. Expression of the gangliosides GM3, GD3, and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma. Int J Cancer 41:336–343.

    Article  PubMed  CAS  Google Scholar 

  88. Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WHJr, Koprowski H. 1986. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lette 208:17–22.

    Article  CAS  Google Scholar 

  89. Hoon DSB, Banez M, Okun E, Morton DL, Irie RF. 1991. Modulation of human melanoma cells by interleukin-4 alone and in combination with y-interferon or a-tumor necrosis factor. Cancer Res 51:2002–2008.

    PubMed  CAS  Google Scholar 

  90. Inokuchi JI, Momosaki K, Shimeno H, Nagamatsu A, Radin NS. 1989. Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells. J Cell Physiol 141:573–583.

    Article  PubMed  CAS  Google Scholar 

  91. Werkmeister JA, Triglia TM, Mackawy IR, Dowling JP, Varigos GA, Morstyn G, Burns GF. 1987. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 31. Cancer Res 47:225–230.

    PubMed  CAS  Google Scholar 

  92. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. 1986. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol 102:688–696.

    Article  PubMed  CAS  Google Scholar 

  93. Cheresh DA, Klier FG. 1986. Disialoganglioside GD2 distributes preferentially into substrate-microprocesses on human melanoma cells during their attachment to fibronectin. J Cell Biol 102:1887–1897.

    Article  PubMed  CAS  Google Scholar 

  94. Tsuchida T, Saxton RE, Irie RF. 1987. Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 78:55–59.

    PubMed  CAS  Google Scholar 

  95. Miyake M, Hakomori S. 1991. A specific cell surface glycoconjugate controlling cell motility: Evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry 30:3328–3334.

    Article  PubMed  CAS  Google Scholar 

  96. Passaniati A, Hart GW. 1989. Sialic acids and penultimate oligosaccharides on metastatic tumor cell surfaces. Biochem Soc Trans 17:33–36.

    Google Scholar 

  97. Humphries MJ, Matsumoto K, White SL, Olden K. 1986. Oligosaccharide modification by swainsonine treatment inhibits pulmonary colonization by B16-F10 murine melanoma cells. Proc Natl Acad Sci USA 83:1752–1756.

    Article  PubMed  CAS  Google Scholar 

  98. Finne J, Castrori S, Feizi T, Burger MM. 1989. Lectin-resistant variants and revenants of mouse melanoma cells: Differential expression of a fucosylated iil-surface antigen and altered metastasizing capacity. Int J Cancer 43:300–304.

    Article  PubMed  CAS  Google Scholar 

  99. Lesot H, Kuhl U, von der Mark K. 1983. Isolation of a laminin-binding protein from muscle cell membranes. EMBO J 2:861–865.

    PubMed  CAS  Google Scholar 

  100. Malinoff HL, Wicha MS. 1983. Isolation of a cell surface receptor protein for laminin from murine fiborsarcoma cells. J Cell Biol 96:1475–1479.

    Article  PubMed  CAS  Google Scholar 

  101. Graf J, Ogle RC, Robey FA, Sasaki M, Martin GR, Tamada Y, Kleinman HK. 1987. A pentapeptide from the laminin Bl chain mediates cell adhesion and binds the 6700 laminin receptor. Biiochemistry 26:6896–6900.

    Article  CAS  Google Scholar 

  102. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y, Martin GR. 1987. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238:1132–1134.

    Article  PubMed  CAS  Google Scholar 

  103. Castruonovo V, Taraboletti G, Sobel ME. 1991. Laminin receptor complementary DNA-deduced synthetic peptide inhibits cancer cell attachment to endothelium. Cancer Res 51:5672–5678.

    Google Scholar 

  104. Wewer UM, Taraboletti G, Sobel ME, Albrechtsen R, Liotta LA. 1987. Role of laminin receptor in tumor cell migration. Cancer Res 47:5691–5698.

    PubMed  CAS  Google Scholar 

  105. Hendrix MJC, Wood WR, Seftor EA, Lotan D, Nakajima M, Mosiorowski RL, Seftor REB, Stetler-Stevenson WG, Bevacqua SJ, Liotta LA, Sobel ME, Raz Abraham, Lotan R. 1990. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 50:4121–4130.

    PubMed  CAS  Google Scholar 

  106. Runyan RB, Versalovic J, Shur BD. 1988. Functionally distinct laminin receptors mediate cell adhesion and spreading: The requirements for surface galactosyltransferase in cell spreading. J Cell Biol 107:1863–1871.

    Article  PubMed  CAS  Google Scholar 

  107. Nakajima M, Irimura T, DiFerrante N, Nicolson GL. 1984. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 259:2283–2290.

    PubMed  CAS  Google Scholar 

  108. Nakajima M, Irimura T, DiFerrante D, DiFerrante N, Nicolson GL. 1983. Heparan sulfate degradation: Relation to tumor invasiveness and metastatic properties of mouse B16 melanoma sublines. Science 220:611–613.

    Article  PubMed  CAS  Google Scholar 

  109. Irimura T, Nakajima M, Nicolson GL. 1986. Chemically modified heparins as inhibitors of heparan sulfate specific endo-β-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 25:5322–5328.

    Article  PubMed  CAS  Google Scholar 

  110. Villanueva GB, Nakajima M, Nicolson GL. 1989. Heparin derivatives as inhibitors of heparanase from metastatic melanoma cells. Ann NY Acad Sci 556:496–498.

    Article  Google Scholar 

  111. Keren Z, Leland F, Nakajima M, LeGrue SJ. 1989. Inhibition of experimental metastasis and extracellular matrix degradation by butanol extracts from B16-F1 murine melanoma. Cancer Res 49:295–300.

    PubMed  CAS  Google Scholar 

  112. Saiki I, Murata J, Nakajima M, Tokura S, Azuma I. 1990. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res 50:3631–3637.

    PubMed  CAS  Google Scholar 

  113. Liotta LA, Abe S, Robey PG, Martin GR. 1979. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 76:2268–2272.

    Article  PubMed  CAS  Google Scholar 

  114. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. 1980. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 84:67–68.

    Article  Google Scholar 

  115. Herlyn D, Iliopoulos D, Jensen PJ, Parmiter A, Baird J, Hotta H, Adachi K, Ross AH, Jambrosic J, Koprowski H, Herlyn M. 1990. In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res 50:2296–2302.

    PubMed  CAS  Google Scholar 

  116. Mignatti P, Robbins E, Rifkin DB. 1986. Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 47:487–498.

    Article  PubMed  CAS  Google Scholar 

  117. Hendrix MJC, Seftor EA, Chu YW, Seftor REB, Nagle RB, McDaniel KM, Leong SPL, Yohem KH, Leibovitz AM, Meyskens FL, Conanway DH, Welch DR, Liotta LA, Stetler-Stevenson W. 1992. Coexpression of vimentin and keratins by human melanoma tumor cells: Correlation with invasive and metastatic potential. J Natl Cancer Inst 84:165–174.

    Article  PubMed  CAS  Google Scholar 

  118. Templeton NS, Stetler-Stevenson WG. 1991. Identification of a basal promoter for the human Mr 72,000 type IV collagenase gene and enhanced expression in a highly metastatic cell line. Cancer Res 51:6190–6193.

    PubMed  CAS  Google Scholar 

  119. Kanemoto T, Reich R, Royce L, Greatorex D, Adler SH, Shiraishi N, Martin GR, Yamada Y, Kleinman HK. 1990. Identification of an amino acid sequence from the laminin A chain that stimulates metastasis and collagenase IV production. Proc Natl Acad Sci USA 87:2279–2283.

    Article  PubMed  CAS  Google Scholar 

  120. Sloane BF, Dunn JR, Honn KV. 1981. Lysosomal cathepsin B: Correlation with metastatic potential. Science 212:1151–1153.

    Article  PubMed  CAS  Google Scholar 

  121. Sloane BF, Honn KV, Sadler JG, Turner WA, Kimpson JJ, Taylor JD. 1982. Cathepsin B activity in B16 melanoma cells: A possible marker for metastatic potential. Cancer Res 41:980–986.

    Google Scholar 

Download references

Authors
  1. M. A. Warso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. W. Boddie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winthrop University Hospital, Mineola, New York, USA

    Larry Nathanson

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Warso, M.A., Boddie, A.W. (1993). The natural history of melanoma, including the pattern of metastatic spread and the biological basis for metastases — staging of melanoma. In: Nathanson, L. (eds) Current Research and Clinical Management of Melanoma. Cancer Treatment and Research, vol 65. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3080-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3080-0_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6345-3

  • Online ISBN: 978-1-4615-3080-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation